Personalis Announces Partnership with Mt. Sinai Services to Offer its ACE Platform for Next Generation Sequencing and Interpretation to Support Tumor Molecular Profiling and Immuno-Oncology Clinical Trials in Canada
Menlo Park, CA – June 6, 2016 – Personalis, Inc., a leading precision medicine company focused on advanced NGS-based clinical diagnostic and research services announced today that the company has entered into a letter of intent (LOI) with Mount Sinai Services, Inc. of Toronto, Ontario, Canada, a global provider of customized clinical laboratory and research services. The LOI contains broad terms for the development of a partnership framework for Personalis and Mount Sinai Services to offer the Personalis patented, and CLIA validated ACE (Accuracy and Content Enhanced) sequencing and analysis technology for clinical diagnostic and research tumor molecular profile sequencing and analysis and immuno-oncology sequencing clinical trials for customers throughout Canada. The ACE Platform® incorporates proprietary sample prep and sequencing processes which produce the highest levels of gene finishing and coverage of difficult-to-sequence regions.
Personalis currently provides comprehensive genomic testing for tumor-profiling through its ACE CancerPlus™ test for solid tumors. As the largest and most comprehensive cancer panel available today, the ACE CancerPlus test combines both DNA and RNA sequencing of over 1,400 genes, using the Personalis proprietary ACE technology. The ACE CancerPlus Test result reports out on 181 genes of clinical relevance, producing comprehensive tumor genomic profile data to guide therapy and ongoing research.
The ACE ImmunoID™ service offers multiple solutions for the comprehensive analysis of tumor mutation burden and neoantigen identification including the leading ACE Cancer Exome and Transcriptome covering over 20,000 genes and the ACE Cancer DNA/RNA Panel available with over 1,400 genes. The Personalis ACE assays and informatics platform achieves industry leading coverage and sensitivity enabling variants to be identified more accurately and reliably in regions that may be completely missed by typical exomes, transcriptomes, and panels. The ACE assays together with advanced informatics are CLIA validated to enable clinical diagnostic and clinical trials use.
“We are pleased to work with Mount Sinai Services to offer the Personalis ACE technology to support immuno-oncology clinical trials and clinical laboratory and research tumor profiling in Canada,” said John West, CEO of Personalis. “Mount Sinai Services has been a leader in advancing personalized medicine in Canada and understands the complexities and value of comprehensive and accurate analysis and interpretation in cancer research and clinical care. Their longstanding reputation for innovation and high quality customer service provides Personalis with a technically robust partner in Canada.”
“As a leading, independent clinical diagnostic and research laboratory with a strong focus on precision medicine and diagnostics, Mount Sinai Services is delighted to work with Personalis to develop this strategic partnership to advance cancer therapeutic development and clinical care,” said Dr. Azar Azad, Managing Director of Mount Sinai Services. “We are confident that our expertise in providing customized laboratory services, combined with the capabilities of the Personalis ACE Platform will contribute to advancing translational medicine by providing a comprehensive solution for pharma discovery and development of cancer therapies, and personalized clinical diagnostic cancer care.”
Mount Sinai Services Contact:
Azar Azad Ph.D.
(416) 586-4800 ext. 7266